[Survival in lung cancer].
On an average of 6-18 months, actual survival in lung carcinoma (only 20% patients live over 1-2 years) is very modest, in spite of remarkable diagnostic and therapeutic efforts. In a research performed on 304 patients (244 men and 60 women), diagnosed between January 1st 2000 and December 31st 2001, we have studied the survival in function of disease extension over 10 months. A comparison of the survival of the patients diagnosed in the IV-th stage and the other stages respectively I-st, II-nd and III-rd has been realised by a statistical study with the help of test chi2. The percentages in the clinical stages I and IV was of 1.64% and respectively of 48.68% and it demonstrates a very modest survival for the patients diagnosed in the stage IV; disease extension represents a decisive factor in the determinism of this disease. Women survival (of 53.33%) better than that of men (of only 48.36%) can be explained by a more reduced smoking (only 63% at women comparative with 87% at men) and by a more reduced exposure to professional carcinogen agents. Statistical analysis of clinical stages I, II and III in comparison with the clinical stage IV by the help of the test X2, demonstrates that there are significant statistical differences between the clinical stage IV and the other clinical stages.
Chiriac
Carmen-Florina
CF
carmenfchiriac@yahoo.com
D002277:Carcinoma / Q000175:diagnosis / Q000401:mortality*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000401:mortality*; D008297:Male; D008432:Mathematical Computing; D009367:Neoplasm Staging; D012189:Retrospective Studies; D012307:Risk Factors; D012383:Romania / Q000453:epidemiology; D015996:Survival Rate